Capital Research Global Investors
DNLI icon

Capital Research Global Investors’s Denali Therapeutics DNLI Stock Holding History

Capital Research Global Investors’s Portfolio DNLI Stock Details DNLI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$66M Buy
2,565,817
+51,229
+2% +$1.05M 0.01% 333
2026
Q1 		$48.3M Sell
2,514,588
-1,214,656
-33% -$24.2M 0.01% 359
2025
Q4 		$61.6M Sell
3,729,244
-1,031,614
-22% -$17.4M 0.01% 338
2025
Q3 		$69.1M Buy
4,760,858
+10,279
+0.2% +$148K 0.01% 324
2025
Q2 		$66.5M Sell
4,750,579
-14,558
-0.3% -$205K 0.01% 322
2025
Q1 		$64.8M Sell
4,765,137
-712,074
-13% -$13.6M 0.01% 339
2024
Q4 		$112M Sell
5,477,211
-2,431,903
-31% -$62.3M 0.02% 291
2024
Q3 		$230M Buy
7,909,114
+782,581
+11% +$19.4M 0.05% 201
2024
Q2 		$165M Buy
7,126,533
+1,076,576
+18% +$20.7M 0.04% 240
2024
Q1 		$124M Buy
6,049,957
+3,140,429
+108% +$59M 0.03% 271
2023
Q4 		$62.4M Buy
2,909,528
+29,205
+1% +$578K 0.02% 307
2023
Q3 		$59.4M Buy
2,880,323
+42,671
+2% +$1.08M 0.02% 315
2023
Q2 		$83.7M Buy
2,837,652
+368,828
+15% +$10.4M 0.02% 291
2023
Q1 		$56.9M Buy
2,468,824
+208,182
+9% +$5.73M 0.02% 316
2022
Q4 		$62.9M Buy
2,260,642
+2,172,875
+2,476% +$64.7M 0.02% 311
2022
Q3 		$2.65M Buy
+87,767
New +$2.85M ﹤0.01% 416

Other funds holding DNLI

T. Rowe Price Investment Management
T. Rowe Price Investment Management Baltimore, Maryland $153B AUM 38.14% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Temasek Holdings
Temasek Holdings Singapore $37.3B AUM 12.6% 1-Year Est. Return
Vanguard Portfolio Management
Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $1.15T AUM 47.82% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

Capital Research Global Investors's DNLI Position: Q2 2026 in Review

Capital Research Global Investors increased its Denali Therapeutics (DNLI) stake by 2% in Q2 2026, buying an estimated $1.05M and bringing the position to 2,565,817 shares worth $66M. The position accounts for 0.01% of the portfolio, ranked #333.

Capital Research Global Investors first reported a position in DNLI in Q3 2022 and has held it in 16 quarters since. The position peaked at $230M in Q3 2024. 294 funds tracked by Wall St. Rank hold DNLI as of Q2 2026.

  • Capital Research Global Investors held 2,565,817 shares of Denali Therapeutics worth $66M as of Q2 2026.
  • Capital Research Global Investors bought 51,229 Denali Therapeutics shares in Q2 2026, an estimated $1.05M.
  • Denali Therapeutics made up 0.01% of Capital Research Global Investors's portfolio in Q2 2026, its #333 holding.
  • Capital Research Global Investors first reported a position in Denali Therapeutics in Q3 2022 and has held it in 16 quarters since.
  • Capital Research Global Investors's Denali Therapeutics position peaked at $230M in Q3 2024.
  • 294 funds tracked by Wall St. Rank held Denali Therapeutics as of Q2 2026.

Based on Capital Research Global Investors's 13F filing for Q2 2026, filed 12 Aug 2026.